Press Releases
Therapeutic Focus
We are developing potentially curative therapies for patients by deploying our genome editing toolbox with a stepwise approach


Effectively addressing disease
Our therapeutic indications were chosen based on our conviction in the underlying biology, existence of validating preclinical and clinical data, availability of pharmacodynamic and translational tools to assess early proof-of-concept, relevant value supporting outcome measures, and, most importantly, ongoing clinical unmet need. These programs are selected to both address devastating diseases and to establish new standards in targetability, precision, efficiency, and scope of editing capabilities. Using our toolbox, we aim to match the optimal genome editing tool to each indication to ensure lasting effects on the lives of patients.
Therapeutic Focus
- Research
- Lead Optimization
- IND-enabling
- Clinical
In vivo
- Research
- Lead Optimization
- IND-enabling
- Clinical
-
-
An illustrated depiction of a human liver, targeting Undisclosed Metabolic Disease Target, Lead optimization 75% completed, in partnership with Moderna
-
An illustrated depiction of a human liver, targeting Hemophilia A, Lead optimization 75% completed
-
An illustrated depiction of a human liver, targeting Undisclosed Disease Target, Research 75% completed
-
An illustrated depiction of a human liver, targeting Undisclosed Cardiovascular Disease Target 1, Research 75% completed
-
An illustrated depiction of a human liver, targeting Undisclosed Cardiovascular Disease Target 2, Research 50% completed
-
-
-
An illustrated depiction of a human brain, targeting Undisclosed CNS Disease Target, Research 50% completed
-
-
-
An illustrated depiction of a human lung, targeting Cystic Fibrosis, Research 25% completed
-
Ex vivo
- Research
- Lead Optimization
- IND-enabling
- Clinical
-
-
An illustrated depiction of a human cell, targeting Immuno-oncology (TCR), Lead optimization 25% completed, in partnership with Affini-T
-
An illustrated depiction of a human cell, targeting Immuno-oncology (Modular CAR-T), Research 50% completed
-
Partnering with Pioneers
-
11.14.22 -
Press Releases
06.15.22 Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients
-
Press Releases
11.02.21 Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
Leveraging next-generation gene editing tools to generate a broad and differentiated therapeutic approach
With our toolbox, we can edit any target in the human genome.